• Inspire Medical Systems recently participated in the SLEEP 2026 APSS meeting in Baltimore, where it showcased its Inspire V system, SleepSync platform, and extensive new clinical and real‑world data for obstructive sleep apnea therapy.
• The company highlighted emerging evidence that hypoglossal nerve stimulation may improve cardiovascular risk markers and healthcare utilization compared with Continuous Positive Airway Pressure and untreated patients, while new screening research could reduce the need for drug‑induced sleep endoscopy.
• We’ll now examine how this fresh cardiovascular and adherence data from SLEEP 2026 could reshape Inspire Medical Systems’ investment narrative.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Inspire Medical Systems Investment Narrative Recap

To own Inspire Medical Systems, you need to believe hypoglossal nerve stimulation can remain a meaningful, reimbursed alternative for obstructive sleep apnea despite slower growth and rising competition. Right now, the key near term catalyst is execution on the Inspire V and SleepSync rollout after the reset in 2026 revenue guidance, while the biggest risk remains reimbursement and adoption pressure in a market shifting toward lower cost, less invasive solutions. The SLEEP 2026 data supports the therapy’s relevance but does not remove these execution and payer risks.

The most relevant new data point for investors is the Target Trial Emulation of Inspire therapy and cardiovascular outcomes, which compared Inspire patients with adherent CPAP, non adherent CPAP, and untreated groups. This study associated Inspire therapy with reductions in more major adverse cardiovascular event categories than CPAP and no treatment. If payers and clinicians accept these findings over time, they could reinforce procedure volumes and support reimbursement, both critical to any recovery in growth and margins.

Yet, against this positive cardiovascular story, the growing risk that payers push harder on reimbursement and steer patients toward cheaper at home alternatives is something investors should be aware of because it could...

Inspire Medical Systems' narrative projects $987.4 million revenue and $67.1 million earnings by 2029.

Uncover how Inspire Medical Systems' forecasts yield a $52.17 fair value, a 22% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts already assumed flat revenue near US$904.2 million and earnings near US$47.7 million by 2029, so SLEEP 2026’s stronger cardiovascular and adherence data may eventually challenge that more pessimistic view or, if reimbursement pressure grows, even reinforce it.

Explore 9 other fair value estimates on Inspire Medical Systems - why the stock might be worth just $45.00!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Inspire Medical Systems research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Inspire Medical Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Inspire Medical Systems' overall financial health at a glance.

No Opportunity In Inspire Medical Systems?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Explore 31 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.